Key facts
- This page summarizes Kirk Allen Coleman's Form 4 filing for TFF Pharmaceuticals, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 Apr 2024, 20:49.
Kirk Allen Coleman - 18 Apr 2024 Form 4 Insider Report for TFF Pharmaceuticals, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 18 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Apr 2024, 20:49:47 UTC
- Prior SEC filing
- 15 Aug 2023
- Next SEC filing
- 08 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kirk Allen Coleman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kirk Allen Coleman filed Form 4 for TFF Pharmaceuticals, Inc. on 22 Apr 2024.
Change
- Previous filing in this sequence was filed on 15 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TFFP
transaction
Derivative
Restricted stock units
Award
- Transaction value
- $0
- Shares
- +5,300
- Change %
- Price
- $0.000000
- Shares after
- 5,300
- Date
- 18 Apr 2024
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 5,300
- Exercise price
- Footnotes
- F1, F2
TFFP
transaction
Derivative
Restricted stock units
Award
- Transaction value
- $0
- Shares
- +10,600
- Change %
- Price
- $0.000000
- Shares after
- 10,600
- Date
- 18 Apr 2024
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 10,600
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted to the Reporting Person, in part, in consideration of their agreement to defer 50% of their cash compensation until such time as the Issuer has completed its next equity financing.
Footnote F2
The settlement of the RSUs is contingent on stockholder approval, at the Issuer's 2024 annual meeting of stockholders, or Annual Meeting, of an amendment to increase the share reserve under the Issuer's 2021 Stock Incentive Plan, or 2021 Plan. The RSUs shall terminate if the Issuer's stockholders do not approve the proposed amendment to the 2021 Plan at the Annual Meeting. Subject to stockholder approval of the amendment to the 2021 Plan, and subject further to the consummation of the Issuer's next equity financing, the RSUs will settle in four equal installments, with the first installment settling on completion of the Issuer's next equity financing and the other three installments settling on the 15th, 30th and 45th day following the completion of the next equity financing.
Footnote F3
Subject to the consummation of the Issuer's next equity financing, the RSUs will settle in four equal installments, with the first installment settling on completion of the Issuer's next equity financing and the other three installments settling on the 15th, 30th and 45th day following the completion of the next equity financing.